Infigratinib (BGJ398)
别名: NVP-BGJ398
目录号:S2183 Purity: 99.9%
Infigratinib (BGJ398) 是一种有效的,选择性FGFR抑制剂,作用于FGFR1/2/3,在无细胞试验中IC50为0.9 nM/1.4 nM/1 nM,作用于FGFR比作用于FGFR4和VEGFR2选择性高40倍以上,对Abl, Fyn, Kit, Lck, Lyn和Yes几乎没有抑制活性。Phase 2。
CAS: 872511-34-7
客户使用Selleck的Infigratinib (BGJ398)发表文献231篇
- Nature, 2024 629(8011):450-457
- Signal Transduct Target Ther, 2024 9(1):65
- Cancer Discov, 2023 13(9):1998-2011
- Mol Cancer, 2022 21(1):156
- Cancer Discov, 2022 12(5):1378-1395
- Nature, 2021 10.1038/s41586-020-03085-8
- Nature, 2021 595(7869):730-734
- Cancer Cell, 2021 S1535-6108(21)00492-X
- Nature, 2020 10.1038/s41586-020-2024-3
- Cell, 2019 36(2):179-193
- Cancer Cell, 2019 36(2):179-193
- Cancer Cell, 2019 36(1):35-50
- Circ Res, 2019 125(1):74-89
- Nat Med, 2018 24(7):968-977
- Ann Oncol, 2017 28(6):1250-1259
- Nature, 2016 30;534(7609):647-51.
- Cancer Cell, 2015 27(1):97-108
- Nat Genet, 2015 47(9):1003-10
- J Thorac Oncol, 2015 10(12):1736-44
- Nat Commun, 2024 15(1):3805
- Clin Cancer Res, 2024 10.1158/1078-0432.CCR-24-1834
- EMBO J, 2024 43(12):2308-2336
- Cell Mol Life Sci, 2024 81(1):471
- J Anim Sci Biotechnol, 2024 15(1):148
- Front Pharmacol, 2024 15:1459820
- BMC Biol, 2024 22(1):222
- Cell Genom, 2024 4(2):100487
- bioRxiv, 2024 2024.08.30.610360
- Cell Rep, 2023 42(8):112838
- Cell Mol Life Sci, 2023 80(10):311
- NPJ Precis Oncol, 2023 7(1):127
- Br J Pharmacol, 2023 10.1111/bph.16186
- Oral Oncol, 2023 146:106562
- Cancers (Basel), 2023 15(22)5354
- Development, 2023 150(18)dev201866
- Sci Rep, 2023 13(1):20223
- Front Neurosci, 2023 17:1251906
- Dis Model Mech, 2023 16(5)dmm049571
- Adv Skin Wound Care, 2023 36(5):249-258
- Research Square, 2023 10.21203/rs.3.rs-3678387/v1
- J Exp Med, 2022 219(6)e20210390
- Dev Cell, 2022 57-19:2273-2289.e11
- Redox Biol, 2022 56:102468
- Cell Death Dis, 2022 13(11):922
- Cell Rep, 2022 39(12):110993
- Cell Rep, 2022 39(1):110608
- JCI Insight, 2022 7(22e158060)
- Oncogene, 2022 10.1038/s41388-022-02558-6
- Oncogene, 2022 10.1038/s41388-022-02270-5
- NPJ Precis Oncol, 2022 6(1):52
- NPJ Precis Oncol, 2022 6(1):11
- NPJ Precis Oncol, 2022 6(1):88
- J Pathol, 2022 10.1002/path.6034
- Oncoimmunology, 2022 11(1):2096349
- iScience, 2022 25(10):105182
- Int J Mol Sci, 2022 24(1)701
- Int J Mol Sci, 2022 23(19)11524
- Front Cell Dev Biol, 2022 10:836179
- Int J Mol Med, 2022 49(6)84
- Cancers (Basel), 2022 14(2)278
- Cancers (Basel), 2022 14(10)2397
- J Pers Med, 2022 12(2)258
- Biomedicines, 2022 10(3)601
- Development, 2022 dev.196220
- J Atheroscler Thromb, 2022 10.5551/jat.63460
- Hum Cell, 2022 10.1007/s13577-022-00671-y
- BMC Cancer, 2022 22(1):478
- Head Neck, 2022 44(5):1192-1205
- PeerJ, 2022 10:e14338
- CA Cancer J Clin, 2022 2(6):510-523.
- Redox Biol, 2021 41:101904
- Cancer Res, 2021 canres.2276.2020
- Cancer Res, 2021 canres.0955.2021
- Proc Natl Acad Sci U S A, 2021 118(29)e2101783118
- EMBO Mol Med, 2021 13(9):e13193
- Cell Rep, 2021 36(4):109455
- NPJ Precis Oncol, 2021 5(1):65
- J Transl Med, 2021 19(1):401
- Breast Cancer Res, 2021 23(1):107
- Liver Int, 2021 41(3):608-620
- Mol Oncol, 2021 10.1002/1878-0261.13145
- Neurobiol Dis, 2021 152:105294
- Cells, 2021 10(4)804
- Int J Mol Sci, 2021 22(4)2179
- J Cell Physiol, 2021 10.1002/jcp.30657
- Front Oncol, 2021 11:650052
- Hum Cell, 2021 34(6):1911-1918
- Hum Cell, 2021 10.1007/s13577-021-00639-4
- Hum Cell, 2021 10.1007/s13577-021-00579-z
- Cancer Med, 2021 10.1002/cam4.4041
- Sci Transl Med, 2020 12(572)eabb5817
- J Exp Med, 2020 3;217(8):e20191805
- Liver Cancer, 2020
- Genome Med, 2020 18;12(1):17
- Cancer Res, 2020 80(21):4655-4667
- EMBO Mol Med, 2020 e11793
- EBioMedicine, 2020 62:103131
- Cell Death Dis, 2020 11(10):884
- Oncogene, 2020 39(17):3507-3521
- Cell Oncol (Dordr), 2020 10.1007/s13402-020-00562-0
- Cells, 2020 9(3)
- Int J Mol Sci, 2020 18;21(8):2825
- Int J Mol Sci, 2020 21(1)
- Int J Mol Sci, 2020 21(20)E7770
- Int J Mol Sci, 2020 21(24)E9405
- Cancers (Basel), 2020 12(7):E1756
- Cancers (Basel), 2020 27;12(5)pii: E1087
- Cancers (Basel), 2020 13;12(2) pii: E436
- Cancers (Basel), 2020 12(6):E1674
- Stem Cells, 2020 10.1002/stem.3260
- Transl Oncol, 2020 13(12):100853
- Sci Rep, 2020 10(1):4546
- Molecules, 2020 8;25(9) pii: E2220
- Hum Cell, 2020 10.1007/s13577-020-00420-z
- J Steroid Biochem Mol Biol, 2020 199:105587
- Mol Imaging Biol, 2020 10.1007/s11307-020-01531-7
- Sci Adv, 2020 6(25):eaaz6699
- Nat Commun, 2019 10(1):2532
- Acta Pharm Sin B, 2019 9(6):1193-1203
- Clin Cancer Res, 2019 10.1158/1078-0432.CCR-18-2779
- Clin Cancer Res, 2019 10.1158/1078-0432
- J Exp Clin Cancer Res, 2019 38(1):481
- Cancer Res, 2019 79(19):5088-5101
- Proc Natl Acad Sci U S A, 2019 116(23):11418-11427
- EBioMedicine, 2019 40:695-709
- Haematologica, 2019 10.3324/haematol.2019.220871
- Cell Rep, 2019 26(1):65-78
- Cell Rep, 2019 28(9):2331-2344
- Cell Rep, 2019 28(9):2358-2372
- Oncogene, 2019 38(37):6399-6413
- Elife, 2019 10.7554/eLife.44306
- Elife, 2019 8
- Br J Pharmacol, 2019 10.1111/bph.14807
- Int J Cancer, 2019 10.1002/ijc.32665
- J Mol Cell Biol, 2019 11(1):26-38
- Oncotarget, 2019 10(1):30-44
- Cancers (Basel), 2019 11(12)
- J Biol Chem, 2019 10.1074/jbc.RA119.010144
- Cancer Res Treat, 2019 51(3):951-962
- Development, 2019 10.1242/dev.185306
- Sci Rep, 2019 9(1):8726
- Molecules, 2019 24(3)
- Hum Cell, 2019 32(3):367-378
- Leuk Res, 2019 78:12-20
- Am J Transl Res, 2019 11(3):1616-1625
- Nat Commun, 2018 9(1):2897
- Biomaterials, 2018 176:106-121
- Cancer Lett, 2018 427:38-48
- Cell Death Dis, 2018 9(10):959
- Cell Rep, 2018 23(13):3798-3812
- Oncogene, 2018 37(14):1926-1938
- Elife, 2018 7
- Elife, 2018 7e36468
- Osteoarthritis Cartilage, 2018 26(11):1551-1561
- Oncogenesis, 2018 7(1):4
- Mol Cancer Ther, 2018 17(7):1526-1539
- J Cell Physiol, 2018 233(4):3295-3305
- Int J Mol Sci, 2018 19(10)
- Oncotarget, 2018
- Oncotarget, 2018 9(76):34306-34319
- Drug Des Devel Ther, 2018 12:4181-4189
- Molecules, 2018 23(10)
- Oncol Rep, 2018 39(2):627-632
- Cell Biol Int, 2018 42(11):1511-1522
- Reproduction, 2018 156(2):163-172
- FEBS Open Bio, 2018 8(5):836-842
- heiDOK, 2018 10.11588/heidok.00025732
- Zhonghua Xue Ye Xue Za Zhi, 2018 39(2):143-147
- Sci Transl Med, 2017 14;9(394):eaah6144
- Nat Commun, 2017 8:15308
- Nat Commun, 2017 8(1):1090
- Clin Cancer Res, 2017 23(4):962-973
- Clin Cancer Res, 2017 23(18):5527-5536
- Proc Natl Acad Sci U S A, 2017 114(32):E6613-E6622
- Oncogene, 2017 36(47):6581-6591
- Oncogene, 2017 10.1038/onc
- Elife, 2017 6
- Osteoarthritis Cartilage, 2017 25(9):1522-1530
- Mol Cancer Ther, 2017 16(10):2130-2143
- Mol Cancer Ther, 2017 10.1158/1535-7163
- J Cell Physiol, 2017 232(12):3762-3774
- Oncotarget, 2017 8(54):91841-91859
- Oncotarget, 2017 8(65):109319-109331
- Int J Oncol, 2017 10.3892/ijo.2017.3913
- Carcinogenesis, 2017 38(11):1063-1072
- Mol Carcinog, 2017 56(1):106-117
- Molecules, 2017 22(12)
- BMC Cancer, 2017
- PLoS One, 2017 12(10):e0185736
- Mol Med Rep, 2017 16(5):6590-6599
- J Anim Sci, 2017 95(12):5365-5377
- Nat Commun, 2016 7:13796
- Theranostics, 2016 6(8):1232-43
- Oncogene, 2016 35(27):3587-97
- Int J Cancer, 2016
- Cancer Sci, 2016 107(11):1667-1676
- Oncotarget, 2016 7(26):39861-39871
- Oncotarget, 2016 7(45):74015-74030
- Oncotarget, 2016 7(50):83424-83436
- J Biol Chem, 2016 291(15):8031-47
- Cellular Signalling, 2016 19;28(6):652-662
- J Immunol, 2016 197(2):504-16
- Biol Reprod, 2016 96(1):185-198
- Cell Tissue Res, 2016 364(2):429-41
- Hum Mol Genet, 2016 25(1):9-23
- Cells Tissues Organs, 2016 201(1):26-37
- Reprod Domest Anim, 2016 51(5):649-56
- Genes Chromosomes Cancer, 2016 55(1):60-8
- Cancer Res, 2015 75(15):3139-46
- Lab Chip, 2015 15(24):4614-24
- Mol Cancer Ther, 2015 14(10):2292-302
- J Cell Physiol, 2015 230(9):2281-98
- Oncotarget, 2015 6(4):2009-22
- PLoS One, 2015 10(5):e0127297
- PLoS One, 2015 10(8):e0134346
- Hum Mol Genet, 2015 24(9):2552-64
- Pulm Pharmacol Ther, 2015 10.1016/j.pupt.2015.03.001
- Oncol Lett, 2015 10(4):2003-2008
- Pathol Oncol Res, 2015 10.1007/s12253-015-9916-9
- Scand J Rheumatol, 2015 6:1-10
- Hepatology, 2014 59(4):1427-34
- Gastric Cancer, 2014 10.1007/s10120-014-0444-1
- Chin Med J (Engl), 2014 127(2):272-8
- J Cell Physiol, 2014 229(11):1647-59
- Mol Cancer Res, 2014 12(7):1042-54
- Neoplasia, 2014 16(1):97-103
- Birth Defects Res C Embryo Today, 2014 102(1):83-100
- Anticancer Drugs, 2014 25(2):183-8
- Chem Biol, 2014 21(10):1310-7
- Cancer Sci, 2013 104(12):1618-25
- Celon Pharma Inc, 2013 Paulina Grygielewicz
化学信息&溶解度
分子量 | 560.48 |
分子式 | C26H31Cl2N7O3 |
CAS号 | 872511-34-7 |
Smiles | CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 27 mg/mL ( 48.17 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 100 mg/mL ( 178.41 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 11 mg/mL ( 19.62 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 |
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。